NMRA · Neumora Therapeutics, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“While the Company expects to be able to obtain additional funding, the current available cash and cash equivalents will not be sufficient to fund the Company’s operating plans for at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| $153.07M | $176.07M | $200.93M | $142.72M | $91.75M | |
| $53.16M | $60.09M | $62.54M | $45.48M | $31.12M | |
| $47K | $208K | $631K | $668K | $594K | |
| $211.23M | $241.16M | $263.46M | $252.1M | $135.87M | |
| -$211.23M | -$241.16M | -$263.46M | -$252.1M | -$135.87M | |
| $4.57M | $2.01M | $0 | — | — | |
| $5.19M | $8.34M | $19.93M | — | — | |
| -$1.48M | $4.36M | $19.86M | $16.44M | $4.97M | |
| — | — | — | — | $18K | |
| -$212.72M | -$236.8M | -$243.61M | -$235.66M | -$130.9M | |
| $30K | $130K | $178K | $268K | — | |
| -$212.75M | -$236.93M | -$243.79M | -$235.93M | -$130.9M | |
| -$212.73M | -$236.99M | -$243.65M | -$235.23M | -$131.68M | |
| USD/shares | -$1.23 | -$1.45 | -$1.53 | -$3.63 | -$4.81 |
| USD/shares | -$1.23 | -$1.45 | -$1.53 | -$3.63 | -$4.81 |
| shares | — | 163.39M | 159.38M | 65.02M | 27.21M |
| shares | — | 163.39M | 159.38M | 65.02M | 27.21M |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2026-06-30 | USD 299,000 | 10-Q filed 2026-08-14 |
| Long-term debt, including current maturities | 2026-06-30 | USD 52,912,000 | 10-Q filed 2026-08-14 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Noncurrent operating lease liabilities | 2026-06-30 | USD 41,000 | 10-Q filed 2026-08-14 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 314 similar-size Biotechnology companies (of 567 listed).